HCA Healthcare (NYSE:HCA) Price Target Raised to $370.00

HCA Healthcare (NYSE:HCA) had its target price lifted by JPMorgan Chase & Co. from $360.00 to $370.00 in a report released on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other research analysts have also recently issued reports on the company. Truist Financial lifted their price objective on HCA Healthcare from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, July 16th. Wolfe Research cut HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research note on Monday, July 28th. Robert W. Baird reiterated a “neutral” rating and set a $336.00 price objective (down previously from $396.00) on shares of HCA Healthcare in a research note on Tuesday, April 15th. Barclays lowered their price objective on HCA Healthcare from $416.00 to $390.00 and set an “overweight” rating for the company in a research note on Monday, July 28th. Finally, Royal Bank Of Canada decreased their price target on HCA Healthcare from $404.00 to $401.00 and set an “outperform” rating for the company in a research note on Monday, July 28th. Nine equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and an average target price of $395.69.

HCA Healthcare Trading Up 0.6%

HCA opened at $366.08 on Monday. The stock has a market cap of $85.66 billion, a PE ratio of 15.39, a PEG ratio of 1.14 and a beta of 1.39. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. The business has a 50 day moving average of $369.84 and a 200-day moving average of $348.28. HCA Healthcare has a 52 week low of $289.98 and a 52 week high of $417.14.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, beating analysts’ consensus estimates of $6.20 by $0.64. The company had revenue of $18.61 billion during the quarter, compared to analysts’ expectations of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the business posted $5.50 EPS. Equities research analysts predict that HCA Healthcare will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, September 16th. HCA Healthcare’s payout ratio is currently 12.11%.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, COO Jon M. Foster sold 15,698 shares of the business’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the completion of the sale, the chief operating officer owned 12,646 shares of the company’s stock, valued at approximately $4,670,420.72. The trade was a 55.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of HCA Healthcare

Several hedge funds have recently bought and sold shares of HCA. Sanders Capital LLC lifted its position in shares of HCA Healthcare by 1.0% in the fourth quarter. Sanders Capital LLC now owns 11,655,563 shares of the company’s stock valued at $3,498,417,000 after acquiring an additional 116,826 shares in the last quarter. Capital World Investors lifted its position in shares of HCA Healthcare by 0.7% in the fourth quarter. Capital World Investors now owns 2,928,452 shares of the company’s stock valued at $878,975,000 after acquiring an additional 19,121 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of HCA Healthcare by 83.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after acquiring an additional 1,091,416 shares in the last quarter. Northern Trust Corp boosted its stake in HCA Healthcare by 12.4% during the fourth quarter. Northern Trust Corp now owns 2,017,971 shares of the company’s stock valued at $605,694,000 after buying an additional 223,248 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in HCA Healthcare by 4.5% during the fourth quarter. Nuveen Asset Management LLC now owns 1,865,771 shares of the company’s stock valued at $560,011,000 after buying an additional 81,105 shares during the last quarter. Institutional investors own 62.73% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.